<DOC>
	<DOCNO>NCT02988089</DOCNO>
	<brief_summary>Helicobacter pylorus ( H. pylorus ) , infect 50 % global population , recognize main risk factor multiple gastric pathology , especially non-cardiac gastric cancer . Strongly evidence support H. pylorus eradication effective approach reduce incidence pathology .</brief_summary>
	<brief_title>Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies Salvage Helicobacter Pylori Treatment</brief_title>
	<detailed_description />
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Pectin</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Tinidazole</mesh_term>
	<mesh_term>Furazolidone</mesh_term>
	<criteria>Consecutive patient 1870 year old persistent H. pylorus infection first second line treatment attempt . Enable undergo upper endoscopy ; Patients gastrectomy , acute GI bleeding advance gastric cancer ; Known suspect allergy study medication ; Taking bismuth antibiotic previous four week , take proton pump inhibitor H2receptor blocker previous two week ; Currently pregnant lactate Inability provide inform consent situation could interfere examination therapeutic protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Helicobacter Pylori Infection</keyword>
	<keyword>Antimicrobial susceptibility testing ( AST )</keyword>
</DOC>